Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients

- Godfrey Wagutu¹, John Gitau^{1,2,3}, Kennedy Mwangi⁴, Mary Murithi⁵, Elias Melly⁸, Alexandra
 R. Harris⁷, Shahin Saved⁶, Stefan Ambs⁷, Francis Makokha^{1*}
- ³ ¹Directorate of Research and Innovation, Mount Kenya University, Thika, Kenya
- 4 ²African Institute for Mathematical Science, Rwanda
- 5 ³Center for Epidemiological Modeling and analysis, Nairobi, Kenya
- 6 ⁴International Livestock Research Institute, Nairobi, Kenya
- ⁵Kabarak University, Nakuru, Kenya
- 8 ⁶Aga Khan University Hospital, Nairobi, Kenya
- 9 ⁷Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, USA
- 10 ⁸National Cancer Institute, Kenya
- 11 * Correspondence:
- 12 Francis Makokha
- 13 fmakokha@mku.ac.ke
- 14 Keywords: Neoantigen, breast cancer, exome-seq, RNA-seq, somatic mutations 15

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOantigensoprotiling in Kenyan BC patients

16 ABSTRACT

Background: The immune response against tumors relies on distinguishing between self and nonself, the basis of cancer immunotherapy. Neoantigens from somatic mutations are central to many immunotherapeutic strategies and understanding their landscape in breast cancer is crucial for targeted interventions. We aimed to profile neoantigens in Kenyan breast cancer patients using genomic DNA and total RNA from paired tumor and adjacent non-cancerous tissue samples of 23 patients.

Methods: We sequenced the genome-wide exome (WES) and RNA, from which somatic mutations were identified and their expression quantified, respectively. Neoantigen prediction focused on human leukocyte antigens (HLA) crucial to cancer, HLA type I. HLA alleles were predicted from WES data covering the adjacent non-cancerous tissue samples, identifying four alleles that were present in at least 50% of the patients. Neoantigens were deemed potentially immunogenic if their predicted median IC50 binding scores were ≤500nM and were expressed [transcripts per million (TPM) >1] in tumor samples.

30 **Results:** An average of 1465 neoantigens covering 10260 genes had <500nM median IC50 binding 31 score and >1 TPM in the 23 patients and their presence significantly correlated with the somatic 32 mutations ($R^2 = 0.570$, P = 0.001). Assessing 58 genes reported in the catalog of somatic mutations in 33 cancer (COSMIC, v99) to be commonly mutated in breast cancer, 44 (76%) produced >2 neoantigens 34 among the 23 patients, with a mean of 10.5 ranging from 2 to 93. For the 44 genes, a total of 477 putative neoantigens were identified, predominantly derived from missense mutations (88%), indels 35 36 (6%), and frameshift mutations (6%). Notably, 78% of the putative breast cancer neoantigens were 37 patient-specific. HLA-C*06:01 allele was associated with the majority of neoantigens (194), 38 followed by HLA-A*30:01 (131), HLA-A*02:01 (103), and HLA-B*58:01 (49). Among the genes of medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoparotiling in Kenyan BC patients

- 39 interest that produced putative neoantigens were MUC17, TTN, MUC16, AKAP9, NEB, RP1L1,
- 40 *CDH23*, *PCDHB10*, *BRCA2*, *TP53*, *TG*, and *RB1*.
- 41 **Conclusions:** The unique neoantigen profiles in our patient group highlight the potential of
- 42 immunotherapy in personalized breast cancer treatment as well as potential biomarkers for prognosis.
- 43 The unique mutations producing these neoantigens, compared to other populations, provide an
- 44 opportunity for validation in a much larger sample cohort.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOantigensoprofiling in Kenyan BC patients

45 INTRODUCTION

Breast cancer is among the most frequent causes of cancer-related mortality in women. Disease 46 47 heterogeneity and limited immunogenicity contribute to the lethality of breast cancer (Benvenuto et al., 48 2019). Immune evasion, an important hallmark of cancer, adds to the complexity of cancer burden 49 through induction of immunosuppression (Bates et al., 2018). Immune checkpoint blockade (CKB) 50 therapy has been developed to target and block immune regulatory molecules (PD-1/PD-L1 and 51 CTLA-4) and in the process reactivate T cell immunity (Touchaei &Vahidi, 2024). This approach has 52 been reported to improve clinical responses and survival, especially in tumors with high mutational 53 burdens, such as lung cancer and melanoma (Shiravand et al., 2022). However, CKB therapy is not 54 universally successful among all patients and shows increased efficacy with higher mutational burden 55 tumors (Brahmer et al., 2015). Another immunotherapy approach that has been tested in clinical studies 56 is the targeting of tumor-associated antigens (TAAs) that are expressed in tumors at abnormally high 57 levels and rarely detectable in normal tissues (Valilou & Rezaei, 2019). One of the limitations of this therapy approach is that many TAAs represent normal self-antigens and thus can be tolerated by T-58 59 cells, resulting in poor immune response (Benvenuto et al., 2019). This poses challenges for 60 applicability in breast cancer because it generally has a lower mutational burden. Thus, CKB and TAAs 61 immunotherapy have had limited success in breast cancer patients (Narang et al., 2019).

Tumor neoantigens are tumor-specific antigens derived from somatic mutations in expressed genes and are presentable to the major histocompatibility complex (MHC) by both class I human leukocyte antigen (HLA-I) molecules present on surface of cancer cell, as well as class II HLA molecules present on professional antigen-presenting cells (Blass & Ott, 2021). This elicits anti-tumor immune responses that have the potential of eliminating the tumor cells with minimal off-target effects (Pan et al., 2018). Neoantigens are encoded in various mutational types, including single nucleotide substitution, insertion and deletions (INDELs), splice sites, stop codons gains and silent change, which

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoptotiling in Kenyan BC patients

69 can result in translational frameshifts or novel open reading frames (Benvenuto et al., 2019). As such, 70 these neoantigens offer an advantage over TAAs in that they are only expressed by cancer cells and 71 not by normal cells, which enables specific recognition by the immune system (Benvenuto et al., 2019). Although some neoantigens are shared among patients, most of them are patient-specific and are not 72 73 subject to immune tolerance mechanisms (Yarchoan et al., 2017). The specificity of neoantigens could 74 provide an opportunity for future personalized therapy in a cancer with a low tumor mutational burden and a high disease heterogeneity, such as breast cancer. Moreover, neoantigens can potentially be used 75 76 as biomarkers in cancer immunotherapy to assess or predict the response of a patient to treatment 77 (Benvenuto et al., 2019).

78 Despite advancements in next generation sequencing and high-performance computing that has 79 resulted in improved cancer immunotherapy research and neoantigen-based treatments, there remains 80 a scarcity of information regarding neoantigens in specific populations from sub-Saharan African 81 countries such as Kenya. This lack of data poses a significant challenge in tailoring immunotherapeutic 82 strategies for breast cancer patients in such regions that have a high cancer burden, especially when 83 compounded by germline ancestral factors and a distinct mutational spectrum that may influence tumor 84 biology and immune response. Thus, it is critical to profile the neoantigen burden in this population to 85 contribute to the global collection of breast cancer immunogenic antigens for future drug development. 86 To this end, we sought to profile neoantigens in Kenyan women diagnosed with breast cancer in silico 87 through analysis of the whole exome and RNA sequencing data from 23 patients. We characterized the 88 mutation burden for each patient using WES, identified gene expression patterns in tumor tissue, and 89 predicted the putative neoantigens incorporating these datasets.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoprofiling in Kenyan BC patients

91 MATERIALS AND METHODS

92 **Patients and samples**

93 Tumor and adjacent normal tissue pairs were obtained from 23 breast cancer patients at the Aga Khan Hospital, Nairobi, Kenya and AIC Kijabe Hospital, Kijabe, Kenya between 2019 and 2021. 94 95 Samples were collected through surgical excision, after which tissues were snap frozen in liquid 96 nitrogen and temporarily stored at Aga Khan Hospital. Frozen tissue samples were shipped to the National Cancer Institute, Bethesda, MD, USA, for sequencing. Prior to tissue collection, all patients 97 98 provided written informed consent and the study was approved by Research and Ethics Committees at 99 Aga Khan University Hospital, Nairobi (Ref: 2018/REC-80) and AIC Kijabe Hospital (KH IERC-100 02718/2019).

101 Whole-exome sequencing (WES) and RNA-sequencing

Genomic DNA was extracted from the samples using the DNeasy Blood and Tissue Kit (Qiagen, 102 103 Hilden, Germany), following manufacturer's instructions. Total RNA was extracted from the frozen 104 tissues using TRIzol reagent (Invitrogen). WES was performed by the company, Psomagen 105 (https://www.psomagen.com/). This service provider is Clinical Laboratory Improvement 106 Amendments-certified and College of American Pathologists (CAP)-accredited, achieving a sequence 107 depth of 250x for tumor tissues and 150x for adjacent non-cancerous tissues, as previously described 108 by us (Tang et al., 2023). Total RNA from the 23 sample pairs was processed by a NCI Leidos core 109 facility, where library preparation was performed using the TruSeq Poly A kit (Illumina, San Diego, 110 USA). Samples were sequenced on a Novaseq system with 150 bp paired-end reads and a depth of 30 111 million reads.

112 Reads mapping and variant calling

For WES, raw reads were quality checked using FASTQC (Andrews, 2010) and results summarized using MultiQC (Ewels et al., 2016). The reads were trimmed for low quality reads and

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoproteining in Kenyan BC patients

115 adapter sequences using Trimmomatic (Bolger et al., 2014) and quality-checked again using FASTQC 116 and MultiQC. All samples passed the QC test after trimming and the reads were aligned using BWA-117 MEM (Li, 2013) to the hg38 human reference genome, where >95% of the reads aligned properly to 118 the genome. The aligned reads were deduplicated and read groups added to the deduplicated bam files 119 using Picard. This was followed by base quality recalibration in GATK (McKenna et al., 2010). 120 Somatic variant calling was performed using MuTect2 (McKenna et al., 2010) in paired tumor-normal 121 mode utilizing the panel of normal option that was derived from normal reads. Variants were 122 normalized using a variant tool set (vt; Tan et al., 2015), filtered using GATK and 123 functional/consequence-annotated using a variant effect predictor (VEP; McLaren et al., 2016). 124 Annotated variants were converted to MAF files using vcf2maf (Kandoth et al., 2020) and concatenated 125 into a single file. The MAF files were imported into R package maftools (Mayakonda et al., 2018) for 126 further processing.

For RNA-seq, a quality check was performed using FASTQC and MultiQC after which the reads were trimmed and quality checked again. All samples passed the quality check and the reads were pseudo-aligned to the hg38 reference genome using Kallisto aligner (Bray et al., 2016) with default settings to obtain count matrix. Alignment statistics showed that over >50% reads mapped uniquely to the genome. The raw counts were normalized into estimated Transcripts Per Million (TPM), and scaled using the average transcript length over samples and the library size by *tximport* (Soneson et al., 2016).

134 Variant expression annotation

VCF files containing the variants were annotated for expression using the vcf-expressionannotator (https://github.com/griffithlab/VAtools) with default setting except for choosing the use of gene names instead of transcripts and thereby ignoring the Ensembl id version. The tool takes the output of Kallisto and adds the data contained in the file to the VEP annotated VCF's INFO column.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoprotiling in Kenyan BC patients

Each of the variant annotated gets its expression value (TPM) added to the annotation information andthis is used to determine the level of variant expression during neoantigen filtering.

141 Neoantigen prediction

142 Human leukocyte antigen (HLA) class I alleles (HLA a, b and c) were predicted from each 143 patient's normal sample exome-seq data using HLA-HD v.1.2.1 (Kawaguchi et al., 2017). Here, the 144 putative HLA reads are aligned to an imputed library of full-length HLA alleles. Neoantigens were 145 then predicted using pVACseq (Hundal et al, 2016) with MHCflurry, MHCnuggetsI, SMM, and 146 SMMPMBEC algorithms and keeping the default parameters, except for turning off the VAF and 147 coverage filters. Here, the neoepitopes that could bind to the patient-specific HLA alleles were 148 predicted from the Immune Epitope Database (IEDB; Vita et al., 2019). This involved matching patient 149 HLA type to the existing IEDB list keeping all amino acids with lengths for 9, 10 and 11-mers. 150 Predicted epitopes were filtered to retain only those with high affinity (IC50 \leq 500nM) and were 151 expressed (transcripts per million, TPM>1) in tumor samples. The bioinformatic analysis workflow is 152 outlined in Figure 1.

Sample summary statistics and the pairwise tests for differences among mutations and neoantigens abundance among the BC subtypes using Wilcoxon test and visualization of the results were performed in R software (R Core Team, 2023).

156 **RESULTS**

157 **Patients and sample characteristics**

The demographic and clinical characteristics of the 23 breast cancer patients are summarized in supplementary Table S1. We grouped the tumors into 3 subtypes based on expression of either the hormone receptors (HR) or human epidermal growth factor receptor 2 (HER2) (Narang et al., 2019): those that were HER2+ regardless of the HR status, those that were negative for all hormone receptors

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoparotiling in Kenyan BC patients

(triple negative breast cancer; TNBC) and those that were HR+ and HER2-. Majority of the samples
were HR+/HER2- constituting 52.2%, followed by HER2+ at 34.8% and TNBC at 13.0%. Most of the
patients had invasive carcinoma (invasive ductal carcinoma, 78.26% and invasive carcinoma; 4.35%).
For tumor grade, 65.22% of the patients had grade 3 tumors (65.22%), while the rest had grade 2 tumors
(34.78%). Clinically, 39.13% of the patients were in stage II, 30.44% in stage III, and 8.7% in stage I
(Table S1).

168 Mutation profiles for the 23 patients

169 Across all genes, the average number of detected mutations in the 23 patients was 2809 170 mutations. Considering the different subtypes, TNBC had the highest average number of mutations at 171 3202, followed by HR+/HER2- at 2757, and HER2+ at 2740 mutations (Figure S1). From the catalog 172 of somatic mutations in cancer (COSMIC, v99), we identified 73 genes reported to be mutated in breast 173 cancer and among those, 62 (84.9%) had at least one mutation in our samples. The mutation frequency 174 among the 62 genes ranged from 1 to 55 mutations per individual. The majority of the mutations were 175 of the missense type, most of which were substitutions of C>T (Figure 2). The top 10 mutated genes 176 among the 62 are shown in Figure 3. Four genes (MUC16, MUC17, TTN, RP1L1) were altered in more 177 than 95% of the patients (Figure 3). Moreover, mutations in genes TP53-ERBB3, PTEN-CFAP46 were 178 found to significantly co-occur, while BRCA1-MUC17 mutations were significantly mutually exclusive 179 (P < 0.05) (Figure 4). Furthermore, the majority of the single nucleotide mutations were substitution of 180 C to T, whereas T to A substitutions were most uncommon. Transitions occurred more frequently than 181 transversion in these substitutions (Figure 5).

182 Neoantigen burden

In an analysis that included all the genes (10260), an average of 1465 neoantigens had a ≤ 500 nM median IC50 binding score and >1 TPM expression level in any of the 23 patients and their presence significantly correlated with the somatic mutations ($R^2=0.570$, P=0.001) (Figure 6). Out of

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoptotiling in Kenyan BC patients

186 the 62 COSMIC genes that were mutated in the tumor tissue, 58 genes produced at least one neoantigen. 187 After filtering for genes that produced at least two neoantigens, 44 genes had a mean of 10.5 188 neoantigens ranging from 2 to 93. A total of 477 putative neoantigens were identified in these 44 genes 189 across the 23 patients (Figure 7) predominantly derived from missense mutations (88%), indels (6%) 190 and frameshift mutations (6%) (Figure 8). Most of the neoantigens were produced in the TNBC subtype 191 with an average of 25 neoantigens, followed by HR+/HER2- at 20 neoantigens and HER2+ with an 192 average of 19 neoantigens (Figure S1). Notably, 78% of the putative breast cancer neoantigens were 193 patient-specific (Table S2). HLA-C*06:01 allele was associated with majority of neoantigens (194), 194 followed by HLA-A*30:01 (131), HLA-A*02:01 (103), and HLA-B*58:01 (49). Among the genes of interest that produced putative neoantigens include MUC17, TTN, MUC16, AKAP9, NEB, RP1L1, 195

196 CDH23, PCDHB10, BRCA2, TP53, TG, RB1 among others (Figure 7, Table S3).

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoprotiling in Kenyan BC patients

198 DISCUSSION

199 We analyzed the mutational burden and predicted the neoantigen repertoire in 23 Kenvan breast 200 cancer patients using WES and RNA sequencing data. Among the different breast cancer subtypes, we 201 found that the TNBC molecular subtype had the highest mutational and neoantigen burden although 202 there was no significant difference among the subtypes (Figure S1, Table S4). This is consistent with 203 other studies (Narang et a., 2019). TNBC origin is not well understood although it is reported to be 204 heterogeneous in nature relying on different signaling pathways such as JAK/STAT, 205 PI3K/AKT/mTOR or NOTCH, cell cycle regulators (TP53) and genome integrity genes (BRCA1/2) 206 (Benvenuto et al., 2019). This makes it a disease that is difficult to manage because we do not have a 207 clear understanding of the molecular mechanisms driving it. Yet, the high mutational and neoantigens 208 burden combined with the patient specificity may provide an untapped opportunity to design and 209 optimize personalized immunotherapy for this subtype.

210 In contrast to most populations where TP53, PIK3CA and GATA3 are the most mutated genes 211 (Pan et al., 2020; Pipek et al., 2023; Tang et al., 2023), in our study population, three genes MUC16, 212 MUC17 and TTN were highly mutated in over 50% of the samples and produced the highest number 213 of neoantigens. MUC16 has been reported to take part in breast cancer progression and metastasis when 214 overexpressed due to its influence on cell cycle and survival through the JAK2/STAT3 pathway 215 (Lakshmanan et al., 2012). It has been reported as one of the highly mutated genes in breast cancer 216 (Wang & Guda, 2016). *MUC16* has also been described as a marker for disease progression, recurrence, 217 and chemotherapy response (Felder et al., 2014). A high mutation frequency for MUC17 and TTN have 218 recently been reported as an unexpected finding in a study of early onset breast cancer (EOBC) in 219 Taiwanese women (Midha et al., 2020). MUC17 may influence chemoresistance and has recently been 220 reported as a driver gene in adult gliomas (Al Amri et al., 2020; Machado & Ferrer, 2023). For TTN, 221 Oh et al. (2020) found that mutations in TTN correlate with tumor mutational burden and high

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoprotiling in Kenyan BC patients

microsatellite instability, which is associated with poor breast cancer prognosis. Thus, the role of *MUC17* and *TTN* should further be investigated on how mutations in them may relate to early onset of breast cancer in Kenyan patients (Tang et al., 2023).

225 We found that TP53 gene mutations significantly co-occurred with ERBB3 mutations and so 226 did mutations in PTEN and CFAP46, whereas BRCA1 and MUC17 mutations never co-occurred. TP53 227 mutations are associated with tumor aggression and are found in about half of HER2-amplified tumors 228 (Marvalim et al., 2023). The TP53 mutations have been implicated in poor prognosis of HER2+ 229 subtypes compared to other subtypes (Dumay et al., 2013). *PTEN* is a tumor suppressor gene, whose 230 mutation has been associated with initiation, progression, and metastasis of breast cancer (Chen et al., 231 2022). On the other hand, although CFAP46 role in breast cancer is not yet clear, gene fusion involving 232 various other genes such as VTI1A (reported to cause the initiation of glioma and other cancers) has 233 been reported to play a role in breast cancer (Tsuge et al., 2019).

234 Breast tumors with either germline or somatic BRCA1 mutations show no difference in their 235 cancer biology, but inherited mutations in this gene confers a very high lifetime risk of developing 236 breast cancer (Milne & Antoniou, 2011; den Brok et al., 2017; Bodily et al., 2020). This could be the 237 reason such mutations do not necessarily need to co-occur with other gene mutations to initiate or 238 promote breast cancer progression. In our study, BRCA1 was not among the highly mutated genes 239 considering all mutations but was among the genes with high number of missense mutations (Figure 240 4). In contrast, MUC17 mutations were among the most prevalent. Given the role of MUC17 mutations 241 in chemoresistance and in early onset breast cancer (Al Amri et al., 2020; Machado & Ferrer, 2023), 242 its high prevalence and exclusive occurrence in the Kenyan samples that are prone to early onset of 243 breast cancer should be investigated further.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoptofiling in Kenyan BC patients

244 Similar to most studies on neoantigen prediction in breast cancer, we have found that 245 neoantigens burden is positively correlated with tumor mutational burden and that neoantigens were 246 patient-specific (Narang et al., 2019; Animesh et al., 2022). Although most of the top 10 mutated genes 247 (80%) were also the top 10 in the number of neoantigens generated, genes like TP53 and PIK3CA that 248 are reported to be highly mutated in most patient cohorts were not among the top 10 mutated genes in 249 this study, but generated among the highest number of neoantigens (Figure 6; Figure 7). ARID1A gene, 250 which showed unique mutational profile in Kenyan population using exome data compared to African 251 American and Asian population (Tang et al., 2023), was not among the highly mutated, but produced 252 neoantigens. We found that most neoantigens were derived predominantly from missense mutations 253 (88%), compared to indels and frameshift mutations (12%). This is consistent with other studies 254 although the majority do not predict neoantigens from indels and frameshift mutations (Morisaki et al., 255 2021). Similar to other studies, the TNBC subtype had more neoantigens, compared to HR+/HER2-256 and HER2+ subtypes (Narang et al., 2019; Morisaki et al., 2021).

257 In our small sample cohort, we have been able to identify putative neoantigens that show 258 patient-specificity and thus are important in tailored treatment. Interestingly, the mutations and 259 neoantigens in this population are predominantly derived from a unique set of genes (MUC16, MUC17, 260 TNT) compared to other populations, which provide an opportunity for validation in a much larger 261 sample cohort. We predicted neoantigens based on binding affinity to HLA class I only as it is the most 262 important class of antigen binding proteins in cancer immunity. However, HLA class II-based 263 neoantigens may also have a role in tumor immune response (Alspach et al., 2019). Moreover, we did 264 not investigate the expression of the predicted neoantigens on tumor cells alongside the MHC class I 265 molecules and their ability to activate T cells. This being a discovery study, validation of the findings 266 need to be done in a larger cohort while addressing the highlighted limitations of this study.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoprotiling in Kenyan BC patients

Taken together, our findings corroborate the neoantigen profile in breast cancer, highlighting the patient specificity in Kenyan population breast cancer mutational and neoantigens signatures. We also describe putative neoantigens that could be used as markers for breast cancer diagnosis, treatment monitoring, and development of novel immunotherapy.

271 Acknowledgment

- 272 We would like to thank the patients for their consent to provide samples and Aga Khan University
- 273 Hospital (Nairobi) and AIC Kijabe Hospital (Kijabe) for granting access to patient samples.

274 Funding

- 275 This work was funded by the National Research Fund Kenya that supported sample collection, and
- 276 by the Center for Cancer Research, National Cancer Institute, USA, that supported the sequencing
- 277 work.

278 Data accessibility

- 279 WES data is accessible at SRA database Accession number: PRJNA913947, while RNA-seq data is
- accessible at the GEO database under Accession number: GSE225846. All other datasets for this study
- are included in the article's Supplementary Material.

282 Authors' contribution

FM conceived the idea and designed the research project, collected the samples and assembled experiment materials. GW, JG, KM and MM performed the data analysis. FM and GW wrote the manuscript. ARH, SS, SA helped with drafting and reviewing the manuscript. All authors contributed to the revision and final editing of the manuscript prior to submission.

287

288

289

290

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoprofiling in Kenyan BC patients

292 References

- 293 Andrews S. (2010). FastQC: a quality control tool for high throughput sequence data. Available
- 294 online at: <u>http://www.bioinformatics.babraham.ac.uk/projects/fastqc</u>
- Al Amri, W. S., Allinson, L. M., Baxter, D. E., Bell, S. M., Hanby, A. M., Jones, S. J., Shaaban, A.
- 296 M., Stead, L. F., Verghese, E. T., & Hughes, T. A. (2020). Genomic and Expression Analyses Define
- 297 MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer. *Molecular Cancer*
- 298 Therapeutics, 19(3), 945–955. <u>https://doi.org/10.1158/1535-7163.MCT-19-0940</u>
- 299 Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W.,
- 300 Lichti, C. F., Esaulova, E., Vomund, A. N., Runci, D., Ward, J. P., Gubin, M. M., Medrano, R. F. V.,
- 301 Arthur, C. D., White, J. M., Sheehan, K. C. F., Chen, A., Wucherpfennig, K. W., ... Schreiber, R. D.
- 302 (2019). MHC-II neoantigens shape tumour immunity and response to immunotherapy. *Nature*, 202 574(7780). (0(-701, https://dxi.org/10.1028/s4158(-010.1071, https://dxi.org/10.1071, https://dxi.org
- 303 *574*(7780), 696–701. <u>https://doi.org/10.1038/s41586-019-1671-8</u>
- Animesh, S., Ren, X., An, O., Chen, K., Lee, S. C., Yang, H., & Fullwood, M. J. (2022). *Exploring the Neoantigen burden in Breast Carcinoma Patients*. <u>https://doi.org/10.1101/2022.03.03.482669</u>
- Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018). Mechanisms of immune evasion in
 breast cancer. BMC cancer, 18(1), 556. https://doi.org/10.1186/s12885-018-4441-3
- Benvenuto, M., Focaccetti, C., Izzi, V., Masuelli, L., Modesti, A., & Bei, R. (2021). Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. *Seminars in cancer*
- 310 *biology*, 72, 65–75. https://doi.org/10.1016/j.semcancer.2019.10.023
- 311 Benvenuto, M., Focaccetti, C., Izzi, V., Masuelli, L., Modesti, A., & Bei, R. (2021). Tumor antigens
- 312 heterogeneity and immune response-targeting neoantigens in breast cancer. *Seminars in Cancer*
- 313 Biology, 72, 65–75. <u>https://doi.org/10.1016/j.semcancer.2019.10.023</u>
- 314 Blass, E., & Ott, P. A. (2021). Advances in the development of personalized neoantigen-based
- 315 therapeutic cancer vaccines. *Nature Reviews Clinical Oncology*, 18(4), 215–229.
- 316 <u>https://doi.org/10.1038/s41571-020-00460-2</u>
- 317 Bodily W.R., Shirts B.H., Walsh T., Gulsuner S., King M.-C., Parker A., Roosan M., Piccolo S.R.
- 318 Effects of Germline and Somatic Events in Candidate BRCA-like Genes on Breast-Tumor
- 319 Signatures. PLoS ONE. 2020;15:e0239197. doi: 10.1371/journal.pone.0239197
- 320 Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina
- 321 sequence data. Bioinformatics, 30(15), 2114–2120. https://doi.org/10.1093/bioinformatics/btu170
- 322 Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S.,
- 323 Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O.,
- 324 Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., ... Spigel, D. R. (2015).
- 325 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. New
- 326 England Journal of Medicine, 373(2), 123–135. <u>https://doi.org/10.1056/NEJMoa1504627</u>

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoproteining in Kenyan BC patients

- 327 Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Near-optimal probabilistic RNA-seq
- 328 quantification. *Nature Biotechnology*, *34*(5), 525–527. <u>https://doi.org/10.1038/nbt.3519</u>
- 329 Chen, J., Sun, J., Wang, Q., Du, Y., Cheng, J., Yi, J., Xie, B., Jin, S., Chen, G., Wang, L., Wang, X.,
- 330 & Wei, H. (2022). Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis.
- 331 Frontiers in Oncology, 12, 825484. <u>https://doi.org/10.3389/fonc.2022.825484</u>
- den Brok W.D., Schrader K.A., Sun S., Tinker A.V., Zhao E.Y., Aparicio S., Gelmon K.A.
- 333 Homologous Recombination Deficiency in Breast Cancer: A Clinical Review. JCO Precis. Oncol.
- 334 2017;1:1–13. doi: 10.1200/PO.16.00031.
- 335 Dumay, A., Feugeas, J., Wittmer, E., Lehmann-Che, J., Bertheau, P., Espié, M., Plassa, L., Cottu, P.,
- 336 Marty, M., André, F., Sotiriou, C., Pusztai, L., & De Thé, H. (2013). Distinct *tumor protein p53*
- 337 mutants in breast cancer subgroups. International Journal of Cancer, 132(5), 1227–1231.
- 338 <u>https://doi.org/10.1002/ijc.27767</u>
- 339 Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016). MultiQC: Summarize analysis results for
- 340 multiple tools and samples in a single report. *Bioinformatics*, *32*(19), 3047–3048.
- 341 https://doi.org/10.1093/bioinformatics/btw354
- 342 Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J.,
- Hu, K., Shojaei, H., Whelan, R. J., & Patankar, M. S. (2014). MUC16 (CA125): Tumor biomarker to
 cancer therapy, a work in progress. *Molecular Cancer*, *13*(1), 129. <u>https://doi.org/10.1186/1476-</u>
 4598-13-129
- 346 Hundal, J., Carreno, B. M., Petti, A. A., Linette, G. P., Griffith, O. L., Mardis, E. R., & Griffith, M.
- 347 (2016). pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. *Genome* 348 *Medicine*, 8(1), 11. https://doi.org/10.1186/s13073-016-0264-5
- 349 Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R., & Matsuda, F. (2017). HLA-HD: An accurate
- HLA typing algorithm for next-generation sequencing data. Human Mutation, 38(7), 788–797.
- 351 https://doi.org/10.1002/humu.23230
- 352 Kandoth, C., Gao, J., Qwangmsk, Mattioni, M., Struck, A., Boursin, Y., Penson, A., & Chavan, S.
- 353 (2018). *mskcc/vcf2maf: Vcf2maf v1.6.16* (v1.6.16) [Computer software].
- 354 <u>https://doi.org/10.5281/ZENODO.593251</u>
- 355 Lakshmanan, I., Ponnusamy, M. P., Das, S., Chakraborty, S., Haridas, D., Mukhopadhyay, P., Lele,
- 356 S. M., & Batra, S. K. (2012). MUC16 induced rapid G2/M transition via interactions with JAK2 for
- increased proliferation and anti-apoptosis in breast cancer cells. *Oncogene*, *31*(7), 805–817.
- 358 <u>https://doi.org/10.1038/onc.2011.297</u>
- Li, H. (2013). *Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.* <u>https://doi.org/10.48550/ARXIV.1303.3997</u>
- 361 Machado, G. C., & Ferrer, V. P. (2023). MUC17 mutations and methylation are associated with poor
- 362 prognosis in adult-type diffuse glioma patients. *Journal of the Neurological Sciences*, 452, 120762.
- 363 <u>https://doi.org/10.1016/j.jns.2023.120762</u>

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoproteining in Kenyan BC patients

- Marvalim, C., Datta, A., & Lee, S. C. (2023). Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics, 13(4), 1421–1442. https://doi.org/10.7150/thno.81847
- $\frac{1}{100} = \frac{1}{100} \frac{$
- Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018). Maftools: Efficient and
 comprehensive analysis of somatic variants in cancer. *Genome Research*, 28(11), 1747–1756.
- 368 <u>https://doi.org/10.1101/gr.239244.118</u>
- 369 McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K.,
- 370 Altshuler, D., Gabriel, S., Daly, M., & DePristo, M. A. (2010). The Genome Analysis Toolkit: A
- 371 MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research*,
- 372 20(9), 1297–1303. <u>https://doi.org/10.1101/gr.107524.110</u>
- 373 McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., &
- Cunningham, F. (2016). The Ensembl Variant Effect Predictor. *Genome Biology*, *17*(1), 122.
 <u>https://doi.org/10.1186/s13059-016-0974-4</u>
- 376 Midha, M. K., Huang, Y.-F., Yang, H.-H., Fan, T.-C., Chang, N.-C., Chen, T.-H., Wang, Y.-T., Kuo,
- 377 W.-H., Chang, K.-J., Shen, C.-Y., Yu, A. L., Chiu, K.-P., & Chen, C.-J. (2020). Comprehensive
- 378 Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients. Cancers, 12(8),
- 379 2089. <u>https://doi.org/10.3390/cancers12082089</u>
- Milne, R. L. & Antoniou, A. C. (2011). Genetic modifiers of cancer risk for BRCA1 and BRCA2
 mutation carriers. Annals of Oncology, 22 (1): i11-i17.
- 382 Morisaki, T., Kubo, M., Umebayashi, M., Yew, P. Y., Yoshimura, S., Park, J.-H., Kiyotani, K., Kai,
- 383 M., Yamada, M., Oda, Y., Nakamura, Y., Morisaki, T., & Nakamura, M. (2021). Neoantigens elicit T
- cell responses in breast cancer. *Scientific Reports*, *11*(1), 13590. <u>https://doi.org/10.1038/s41598-021-</u>
- 385 <u>91358-1</u>
 - 386 Narang, P., Chen, M., Sharma, A. A., Anderson, K. S., & Wilson, M. A. (2019). The neoepitope
 - landscape of breast cancer: Implications for immunotherapy. *BMC Cancer*, *19*(1), 200.
 https://doi.org/10.1186/s12885-019-5402-1
- 389 Oh, J.-H., Jang, S. J., Kim, J., Sohn, I., Lee, J.-Y., Cho, E. J., Chun, S.-M., & Sung
- Oh, J.-H., Jang, S. J., Kim, J., Sohn, I., Lee, J.-Y., Cho, E. J., Chun, S.-M., & Sung, C. O. (2020).
 Spontaneous mutations in the single TTN gene represent high tumor mutation burden. *Npj Genomic*
- 391 *Medicine*, *5*(1), 33. https://doi.org/10.1038/s41525-019-0107-6
- 392 Pan, J.-W., Zabidi, M. M. A., Ng, P.-S., Meng, M.-Y., Hasan, S. N., Sandey, B., Sammut, S.-J., Yip,
- 393 C.-H., Rajadurai, P., Rueda, O. M., Caldas, C., Chin, S.-F., & Teo, S.-H. (2020). The molecular
- 394 landscape of Asian breast cancers reveals clinically relevant population-specific differences. *Nature*
- 395 *Communications*, 11(1), 6433. <u>https://doi.org/10.1038/s41467-020-20173-5</u>
- 396 Pan, R.-Y., Chung, W.-H., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., & Hung, S.-I. (2018).
- Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. *Journal of Immunology Research*, 2018, 1–9. https://doi.org/10.1155/2018/4325874
- 399 Pipek, O., Alpár, D., Rusz, O., Bödör, C., Udvarnoki, Z., Medgyes-Horváth, A., Csabai, I., Szállási,
- 400 Z., Madaras, L., Kahán, Z., Cserni, G., Kővári, B., Kulka, J., & Tőkés, A. M. (2023). Genomic


medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCantigensoproteining in Kenyan BC patients

- 401 Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort. *International Journal*
- 402 of Molecular Sciences, 24(10), 8553. <u>https://doi.org/10.3390/ijms24108553</u>
- 403 R Core Team (2023). R: A language and environment for statistical computing. R Foundation for 404 Statistical Computing, Vienna, Austria. URL https://www.R-project.org/
- Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H.,
 Ladwa, R., O'Byrne, K., & Kulasinghe, A. (2022). Immune Checkpoint Inhibitors in Cancer
- Ladwa, R., O'Byrne, K., & Kulasinghe, A. (2022). Immune Checkpoint Inhibitors in Cancer
 Therapy. *Current Oncology*, *29*(5), 3044–3060. https://doi.org/10.3390/curroncol29050247
- 407 Therapy. Current Oncology, 29(5), 3044–3060. <u>https://doi.org/10.3390/curroncol2905024/</u>
- 408 Soneson, C., Love, M. I., & Robinson, M. D. (2016). Differential analyses for RNA-seq: Transcript-
- 409 level estimates improve gene-level inferences. *F1000Research*, *4*, 1521.
- 410 <u>https://doi.org/10.12688/f1000research.7563.2</u>
- 411 Tan, A., Abecasis, G. R., & Kang, H. M. (2015). Unified representation of genetic variants.
- 412 Bioinformatics, 31(13), 2202–2204. https://doi.org/10.1093/bioinformatics/btv112
- 413 Tang, W., Zhang, F., Byun, J. S., Dorsey, T. H., Yfantis, H. G., Ajao, A., Liu, H., Pichardo, M. S.,
- 414 Pichardo, C. M., Harris, A. R., Yang, X. R., Figueroa, J. D., Sayed, S., Makokha, F. W., & Ambs, S.
- 415 (2023). Population-specific Mutation Patterns in Breast Tumors from African American, European
- 416 American, and Kenyan Patients. *Cancer Research Communications*, 3(11), 2244–2255.
- 417 <u>https://doi.org/10.1158/2767-9764.CRC-23-0165</u>
- 418 Touchaei, Z. A., & Vahidi, S. (2024). MicroRNAs as regulators of immune checkpoints in cancer
- 419 immunotherapy: Targeting PD-1/PD-L1 and CTLA-4 pathways. *Cancer Cell International*, 24(1),
 420 102. https://doi.org/10.1186/s12935-024-03293-6
- 421 Tsuge, S., Saberi, B., Cheng, Y., Wang, Z., Kim, A., Luu, H., Abraham, J. M., Ybanez, M. D.,
- 422 Hamilton, J. P., Selaru, F. M., Villacorta-Martin, C., Schlesinger, F., Philosophe, B., Cameron, A.
- 423 M., Zhu, Q., Anders, R., Gurakar, A., & Meltzer, S. J. (2019). Detection of Novel Fusion Transcript
- 424 VTI1A-CFAP46 in Hepatocellular Carcinoma. *Gastrointestinal Tumors*, 6(1–2), 11–27.
- 425 <u>https://doi.org/10.1159/000496795</u>
- Valilou, S. F., & Rezaei, N. (2019). Tumor Antigens. In *Vaccines for Cancer Immunotherapy* (pp. 61–74). Elsevier. https://doi.org/10.1016/B978-0-12-814039-0.00004-7
- 428 Vita, R., Mahajan, S., Overton, J. A., Dhanda, S. K., Martini, S., Cantrell, J. R., Wheeler, D. K.,
- Sette, A., & Peters, B. (2019). The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Research*, 47(D1), D339–D343. <u>https://doi.org/10.1093/nar/gky1006</u>
- 431 Wang, X., & Guda, C. (2016). Integrative exploration of genomic profiles for triple negative breast
- 432 cancer identifies potential drug targets. *Medicine*, 95(30), e4321.
 433 https://doi.org/10.1097/MD.00000000004321
- 434 Yarchoan, M., Johnson, B. A., 3rd, Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017). Targeting
- 435 neoantigens to augment antitumour immunity. Nature reviews. Cancer, 17(4), 209–222.
- 436 https://doi.org/10.1038/nrc.2016.154

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoproteining in Kenyan BC patients







439

440 **Figure 1:** Workflow for neoantigen prediction from WES and RNA sequencing data. Fastq files


441 were quality checked, trimmed and aligned to the hg38 genome. Variant calling was performed

following GATK best practice, while gene expression was quantified using Kallisto. Variants were

443 annotated and expression data added, after which neoantigen prediction was performed in PVACseq

444 pipeline

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensopatotiling in Kenyan BC patients



446

Figure 2: Mutational profiles in 23 patients for 73 genes reported to be mutated in breast cancer. A)
variant classes abundance in the total mutations, B) variant types that include single nucleotide
polymorphism (SNP), insertions (INS) and deletions (DEL), C) proportion of different single


450 nucleotide variant (SNV), **D**) distribution of variants per sample with colors representing the different

451 variant classes denoted in A, E) summary of the variant classes distribution and numbers in all

452 samples, F) Top 10 mutated genes, with colors representing different variant classes and the


453 percentages indicating the proportion of samples in which the genes mutations are present.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNOAntigensoprotiling in Kenyan BC patients




- 455456 Figure 3: Top 10 genes mutated in >50% of the samples. Each color corresponds to a variant class
- 457 listed at the bottom of the figure apart from gray, which indicates absence of mutation.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoprotiling in Kenyan BC patients



- 460 Figure 4: Probability of mutations in any two genes co-occurrence or being mutually exclusive in the
- 461 breast cancer genes for the 23 Kenyan patients. The numbers in parenthesis alongside each gene
- 462 represents the number of missense mutations for that gene in the samples.
- 463




464

465 Figure 5: A) Percentage of various substitution types in all samples, B) percentage of transversions

466 (interchange of purines for pyrimidine) and transition (interchange of either purines or pyrimidines)467 for all samples, C) percentage of the substitutions in each of the samples with colors denoting the

467 for all samples, C) percentage of the substitutions in each of the samples with colors denoting the 468 various types in A.




470

Figure 6: Correlation between tumor mutational burden and neoantigen burden for all the genes in

472 the 23 patients. The neoantigens are filtered for high affinity (IC50 \leq 500nM) and expression

473 (transcripts per million, TPM>1) in tumor samples.


medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensopatotiling in Kenyan BC patients



Frequency
Figure 7: Frequency of neoantigens derived from the COSMIC genes that were mutated in the tumor

477 tissue and produced >1 neoantigens for the 23 patients.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNOantigensoprotiling in Kenyan BC patients




479 Neoantigens Missense Frameshift Indel
480 Figure 8: Summary of mutation types that produced putative neoantigens for the COSMIC genes
481 that were mutated in the tumor tissue in the 23 Kenyan patients.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309133; this version posted June 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wagutu et al. It is made available under a CC-BY-NCNCOAntigensoproteining in Kenyan BC patients

499 Supplementary Materials





501SubtypesSubtypes502Figure S1: Statistical pairwise test (Wilcoxon's test) for differences in mutational burden (A) and503neoantigens counts (B) for the 23 samples.

504

506

505 **Table S1:** Sample characteristics of the 23 Kenyan patients used in this study.

507 **Table S2:** Putative neoantigens for each of the 23 Kenyan patients. Cells in red indicate that the neoantigen is shared by at least 2 patients.

509

510 **Table S3:** Summary of the roles of the top ten genes that generated a high number of neoantigens.

511

512 **Table S4:** Summary of total mutations and proportion of mutation types, total neoantigens, filtered

total neoantigens (filtered for high affinity (IC50 \leq 500nM) and expression [transcripts per million,

514 TPM>1] in tumor samples) and filtered putative neoantigens from COSMIC 44 genes mutated in

515 tumor tissue, and proportion of mutation types that generated them per breast cancer subtype for the

516 23 samples